Business Wire

OH-FRISS

21.9.2022 07:01:42 CEST | Business Wire | Press release

Share
FRISS Launches Industry's First Trust Automation Platform

Good processes are at the heart of maintaining customer trust. There is however a key factor holding back the speed of insurance: trust. Therefore, FRISS today announced the launch of their Trust Automation Platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220920005675/en/

While trust is important in any industry, it’s of ultimate importance in ours – it’s the very concept insurance is built on. The conditions that shape the landscape have brought trust directly to the forefront of conducting good business. Trust is hard to maintain in service-based businesses, in part due to the volume of interactions.

The Trust Automation Platform allows insurers to improve operational efficiency following the 3 pillars of trust:

  1. Standardize, safeguard and automate competence; deliver products & services through process excellence & know-how
  2. Increase customer satisfaction by showing your motives; driven by the intention to do what’s best for your customers you interact with and think how to balance the needs for different groups when needed
  3. Enable fair processes and treatment of customers. Processes should be open and transparent, both for trustworthy customers as for those you need to verify.

“Trust is easily shaken and is nearly impossible to regain once lost. Customers will move to another insurer if interactions are not satisfying. Our Trust Automation Platform provides immediate informational fairness,” explains Jeroen Morrenhof, CEO and Co-Founder of FRISS. “Every result comes with the underlying rationale and is executed in a consistent, accurate and unbiassed manner, while maintaining the opportunity to add subject matter expertise when needed.”

According to Gartner Research, customer trust will replace customer experience (CX) as the foremost strategic term for positioning and messaging of differentiated services. Organizations that can instill digital trust will be able to participate in 50% more ecosystems to expand revenue generation opportunities.1 It is time to start building the relationships your customers demand and deserve.

“In today’s world, we are quick to assess how we are treated in personal interactions with a company. Technology can be used to help in the process. It allows for normalization and standardization of high volume processes, while still allowing highly trained staff to provide feedback and support exceptions when necessary,” adds Christian van Leeuwen, FRISS Co-Founder and CSO. “It’s difficulty lies in interactions with lots of individual cases that together make up a group. By launching the Trust Automation Platform, we will unlock new avenues most insurers would have never thought possible.”

About FRISS

FRISS is the leading provider of Trust Automation for P&C insurers. Real-time, data-driven scores and insights give instant confidence and understanding of the inherent risks of all customers and interactions.

Based on next generation technology, the Trust Automation Platform allows you to confidently manage trust throughout the insurance value chain – from the first quote all the way through claims and investigations when needed.

Thanks to FRISS, trust is normalized throughout the organization, enabling consistent processes to flag high risks in real time. www.friss.com

1 Penny Gillespie, Nadine LeBlanc, Dale Kutnick: “Digital Trust Drives Customer Satisfaction and Business Results”(1 March 2022)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005675/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye